Bris­tol My­er­s' Zeposia ex­pan­sion plans hit by Phase 3 set­back in Crohn's dis­ease

One of Bris­tol My­ers Squibb’s top new im­munol­o­gy prod­ucts has failed a Phase 3 study, dent­ing hopes of grow­ing the fran­chise through a new in­di­ca­tion.

Zeposia, an oral S1P mod­u­la­tor, is al­ready ap­proved to treat mul­ti­ple scle­ro­sis and ul­cer­a­tive col­i­tis. But when giv­en to adults with mod­er­ate to se­vere ac­tive Crohn’s dis­ease, it failed to meet the pri­ma­ry end­point of clin­i­cal re­mis­sion at week 12 ver­sus place­bo, Bris­tol My­ers re­vealed Thurs­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.